<DOC>
	<DOCNO>NCT02968394</DOCNO>
	<brief_summary>The purpose study evaluate omalizumab co-treatment may allow reintroduction honey bee venom immunotherapy patient immunotherapy treatment failure due systemic reaction .</brief_summary>
	<brief_title>Omalizumab Treatment Venom Immunotherapy With Systemic Reactions</brief_title>
	<detailed_description>Some honey bee venom allergic patient treat venom immunotherapy due systemic reaction immunotherapy - immunotherapy failure due systemic reaction . High basophil allergen sensitivity risk factor venom immunotherapy failure due systemic reaction . Omalizumab decrease basophil sensitivity . Venom immunotherapy failure patient co-treated omalizumab another attempt immunotherapy introduction . Patients clinically immunologically follow introduction .</detailed_description>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>severe anaphylactic reaction honeybee sting ( Mueller grade III IV ) confirm sensitization honeybee venom , honeybee venom immunotherapy treatment failure due systemic reaction . systemic mastocytosis , pregnancy , use betaadrenergic blocking agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>